About
KOMO Biosciences develops a non-viral genome engineering platform that uses proprietary hyperactive integrases to precisely and efficiently insert large DNA payloads into various cell types for applications across therapeutics, bioprocessing, agriculture, and industrial biotechnology.
Explore KOMO Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.